home / stock / sera / sera news


SERA News and Press, Sera Prognostics Inc. From 03/22/23

Stock Information

Company Name: Sera Prognostics Inc.
Stock Symbol: SERA
Market: NASDAQ
Website: seraprognostics.com

Menu

SERA SERA Quote SERA Short SERA News SERA Articles SERA Message Board
Get SERA Alerts

News, Short Squeeze, Breakout and More Instantly...

SERA - Sera Prognostics, Inc. (SERA) Q4 2022 Earnings Call Transcript

2023-03-22 20:56:07 ET Sera Prognostics, Inc. (SERA) Q4 2022 Earnings Conference Call March 22, 2023 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners, IR Greg Critchfield - President and CEO Jay Moyes - CFO Conference Call Participants ...

SERA - Sera Prognostics GAAP EPS of -$0.31 beats by $0.07, revenue of $65M beats by $64.87M

2023-03-22 16:26:47 ET Sera Prognostics press release ( NASDAQ: SERA ): Q4 GAAP EPS of -$0.31 beats by $0.07 . Revenue of $65M (+150.0% Y/Y) beats by $64.87M . Total operating expenses were $10.5 million, down from $12.6 million for the fourth quarter of 2021...

SERA - SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS PR Newswire SALT LAKE CITY , March 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innova...

SERA - Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023 PR Newswire SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: S...

SERA - 3 Common Myths About Penny Stocks Debunked 

Debunking the 3 Most Common Myths About Penny Stocks Penny stocks have long been a popular topic of debate in the world of investing. Often misunderstood and unfairly maligned, penny stocks have been the subject of a number of common myths and misconceptions that have led many investors t...

SERA - Sera climbs 62% as study for preterm birth test succeeds

Health diagnostic company Sera Prognostics ( NASDAQ: SERA ) jumped ~62% pre-market Wednesday after announcing that its PreTRM test and physician care met the key goals in a study designed to evaluate its health benefits. The AVERT PRETERM TRIAL assessed infant health benefits when...

SERA - Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL

Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL PR Newswire PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay SALT LAKE CITY , ...

SERA - FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS

FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS PR Newswire – Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its empl...

SERA - SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS PR Newswire - Clinical and economic benefits of the PreTRM® test and treat strategy illustrated...

SERA - Sera Prognostics, Inc. (SERA) Q3 2022 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) Q3 2022 Earnings Conference Call November 9, 2022, 05:00 PM ET Company Participants Peter DeNardo - CapComm Partners, IR Greg Critchfield - President and CEO Jay Moyes - CFO Conference Call Participants Patrick Donnelly -...

Previous 10 Next 10